EFTR
Effector Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
2,352
P/E Ratio
—
EPS
$-12.57
Beta
2.42
52W High
$0.00
52W Low
$0.00
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Effector Therapeutics Inc
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company dedicated to redefining cancer treatment through the innovative modulation of RNA translation to selectively target tumor growth. With a robust pipeline of small molecule therapies, the company is strategically positioned to address critical unmet needs within oncology. Focused on advancing precision medicine, Effector Therapeutics aims to improve treatment outcomes and enhance the quality of life for cancer patients, all while navigating the dynamic landscape of biotechnology innovation.
Fundamentals
| Revenue (TTM) | 675,000 |
| Gross Profit (TTM) | $-21.62M |
| EBITDA | $-32.59M |
| Operating Margin | 0.00% |
| Return on Equity | -947.00% |
| Return on Assets | -83.30% |
| Revenue/Share (TTM) | $0.35 |
| Book Value | $0.21 |
| Price-to-Book | 0.00 |
| Price-to-Sales (TTM) | 69.65 |
| EV/Revenue | - |
| EV/EBITDA | -0.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 117.00% |
| Shares Outstanding | $4.70M |
| Float | $4.67M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
More HEALTHCARE Stocks
Data last updated: 5/25/2026